Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease

Infliximab (Remicade), a chimeric monoclonal antibody to tumor necrosis factor‐alpha (anti–TNF‐α), is being used with increasing frequency in the treatment of Crohn's disease. Infliximab's safety profile to date has been good with reported adverse events being mild to moderate. We report a...

Full description

Saved in:
Bibliographic Details
Published in:Inflammatory bowel diseases 2004-05, Vol.10 (3), p.274-277
Main Authors: Panagi, Sofia, Palka, Wojciech, Korelitz, Burton I., Taskin, Metin, Lessnau, Klaus D.
Format: Article
Language:English
Subjects:
Adult
alveolar hemorrhage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Crohn Disease - drug therapy
Female
Gastrointestinal Agents - adverse effects
Gastrointestinal Agents - therapeutic use
Hemorrhage - chemically induced
Humans
Infliximab
infliximab Crohn's disease
Pneumonia - chemically induced
Pneumonia - diagnosis
Pulmonary Alveoli - pathology
Tomography, X-Ray Computed
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Infliximab (Remicade), a chimeric monoclonal antibody to tumor necrosis factor‐alpha (anti–TNF‐α), is being used with increasing frequency in the treatment of Crohn's disease. Infliximab's safety profile to date has been good with reported adverse events being mild to moderate. We report a case of diffuse alveolar hemorrhage after the second infliximab infusion in a patient with Crohn's disease. The mechanism by which infliximab may have caused the observed pulmonary insult remains unknown. Physicians should be aware of the possible association between infliximab treatment and the development of alveolar hemorrhage. Future cases should be reported.
ISSN:1078-0998
1536-4844
DOI:10.1097/00054725-200405000-00016